Drugs / AMUBARVIMAB
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04691180 | Jan → Sep 2021 | COVID-19 | Brii Biosciences Limited | Completed | No outcome recorded |
| Phase 1 | NCT04479631 | Jul 2020 → Jan 2021 | COVID-19 | Brii Biosciences Limited | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04787211 | Jun → Dec 2021 | COVID-19 | Brii Biosciences Limited | Completed | No outcome recorded |
| Phase 2 | NCT04770467 | Feb 2021 → Oct 2022 | COVID-19 | Brii Biosciences Limited | Withdrawn | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04518410 | Aug 2020 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05780424 | Dec 2020 → Jun 2021 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04501978 | Aug 2020 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMUBARVIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650382 ↗ |
| Known as | BRII-196 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04518410 ↗ |
| Modality | Monoclonal antibody | “BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults.” PMID 36147329 ↗ Sep 2022 |
| Route | Intravenous | “BRII-196 given intravenously” NCT04479631 ↗ |